• Adagio Medical launched an IDE clinical study of its next-generation vCLAS Ultra ventricular ablation system for sustained monomorphic ventricular tachycardia.
• Results have not been presented; the update covers the first patient treated several weeks ago at Banner – University Medical Center Phoenix.
• The procedure was reported as successful, with the patient doing well weeks later, supporting the system’s safety and effectiveness profile.
• Trial data are intended to support a PMA supplement, while the first-generation vCLAS system’s PMA remains under FDA review.
• Management expects the new system to streamline workflow and shorten procedures, strengthening its VT ablation positioning if confirmed in the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260916160758) on September 16, 2026, and is solely responsible for the information contained therein.